Physician profile
Edward Stark
NPI 1093727166
$3,266.22
in general payments reported to CMS, 2019-2025
30 companies · $52.22 in 2025
The $52.22 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $331 · 2021: $1,175 · 2022: $555 · 2023: $566 · 2024: $35.57 · 2025: $52.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $587.21 | 2021-2023 | Urolift |
| Astellas Pharma US INC | $303.48 | 2019-2023 | Xtandi |
| Dendreon Pharmaceuticals LLC | $233.31 | 2019-2023 | Provenge |
| Myovant Sciences INC. | $197.19 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $173.55 | 2020-2023 | Lynparza |
| Pfizer INC. | $156.77 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $150.95 | 2021-2025 | Pifeltro, Lynparza, Keytruda |
| Boston Scientific Corporation | $150.58 | 2019-2025 | Axonics |
| Endo Pharmaceuticals INC. | $142.24 | 2019-2023 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $131.21 | 2023 | Orgovyx |
| Janssen Biotech, INC. | $111.35 | 2019-2022 | |
| Neotract INC. | $106.63 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $106.59 | 2021-2022 | |
| Amgen INC. | $82.19 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.14 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $71.17 | 2022-2023 | |
| Myriad Genetic Laboratories, INC. | $68.12 | 2021-2023 | Prolaris |
| Travere Therapeutics, INC. | $59.76 | 2019-2021 | |
| Foundation Medicine, INC. | $51.33 | 2021 | |
| Olympus America INC. | $49.33 | 2021-2023 | Itind System |
| Baxter Healthcare | $39.60 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $39.51 | 2019-2020 | |
| Antares Pharma, INC. | $38.48 | 2019-2024 | Xyosted |
| Alnylam Pharmaceuticals INC. | $33.75 | 2021 | |
| Acerus Pharmaceuticals Corporation | $24.33 | 2020 | |
| Viiv Healthcare Company | $20.81 | 2024 | Dovato |
| Halozyme INC | $16.72 | 2023 | |
| Laborie Medical Technologies Corp. | $15.21 | 2023 | |
| Urogen Pharma, INC. | $15.18 | 2021 | |
| Photocure INC | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.